Literature DB >> 16384600

Interactions of quinoline antimalarials with hematin in solution.

Timothy J Egan1.   

Abstract

Quinoline antimalarial drugs such as chloroquine and related compounds are believed to act by targeting ferriprotoporphyrin IX (Fe(III)PPIX) in the form of hematin (H(2)O/HO-Fe(III)PPIX), its mu-oxo dimer ([Fe(III)PPIX](2)O) or crystalline beta-hematin ([Fe(III)PPIX](2)) in the malaria parasite. Fe(III)PPIX is formed when the parasite digests host hemoglobin during its intraerythrocytic blood stage. This has led to a number of studies on the interaction of Fe(III)PPIX with quinoline antimalarials and related compounds. This article reviews the spectroscopy, thermodynamics and structures of Fe(III)PPIX-quinoline complexes in solution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16384600     DOI: 10.1016/j.jinorgbio.2005.11.005

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  25 in total

Review 1.  Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors.

Authors:  Ernst Hempelmann
Journal:  Parasitol Res       Date:  2006-11-17       Impact factor: 2.289

2.  Insights into structural and physicochemical properties required for β-hematin inhibition of privileged triarylimidazoles.

Authors:  Clinton G L Veale; Janeeka Jayram; Shivani Naidoo; Dustin Laming; Tarryn Swart; Tania Olivier; Matthew P Akerman; Katherine A de Villiers; Heinrich C Hoppe; Vineet Jeena
Journal:  RSC Med Chem       Date:  2019-12-16

3.  Antimalarials inhibit hematin crystallization by unique drug-surface site interactions.

Authors:  Katy N Olafson; Tam Q Nguyen; Jeffrey D Rimer; Peter G Vekilov
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

4.  Synthesis, structure-activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds.

Authors:  Steven J Burgess; Jane X Kelly; Shawheen Shomloo; Sergio Wittlin; Reto Brun; Katherine Liebmann; David H Peyton
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

Review 5.  A physico-biochemical study on potential redox-cyclers as antimalarial and anti-schistosomal drugs.

Authors:  Laure Johann; Don Antoine Lanfranchi; Elisabeth Davioud-Charvet; Mourad Elhabiri
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Phosphomimetic substitution at Ser-33 of the chloroquine resistance transporter PfCRT reconstitutes drug responses in Plasmodium falciparum.

Authors:  Cecilia P Sanchez; Sonia Moliner Cubel; Britta Nyboer; Monika Jankowska-Döllken; Christine Schaeffer-Reiss; Daniel Ayoub; Gabrielle Planelles; Michael Lanzer
Journal:  J Biol Chem       Date:  2019-07-08       Impact factor: 5.157

7.  The single crystal X-ray structure of β-hematin DMSO solvate grown in the presence of chloroquine, a β-hematin growth-rate inhibitor.

Authors:  Johandie Gildenhuys; Tanya le Roex; Timothy J Egan; Katherine A de Villiers
Journal:  J Am Chem Soc       Date:  2013-01-09       Impact factor: 15.419

8.  Interference with hemozoin formation represents an important mechanism of schistosomicidal action of antimalarial quinoline methanols.

Authors:  Juliana B R Corrêa Soares; Diego Menezes; Marcos A Vannier-Santos; Antonio Ferreira-Pereira; Giulliana T Almeida; Thiago M Venancio; Sergio Verjovski-Almeida; Vincent K Zishiri; David Kuter; Roger Hunter; Timothy J Egan; Marcus F Oliveira
Journal:  PLoS Negl Trop Dis       Date:  2009-07-14

9.  Novel antimalarial aminoquinolines: heme binding and effects on normal or Plasmodium falciparum-parasitized human erythrocytes.

Authors:  Fausta Omodeo-Salè; Lucia Cortelezzi; Nicoletta Basilico; Manolo Casagrande; Anna Sparatore; Donatella Taramelli
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

Review 10.  Molecular and physiologic basis of quinoline drug resistance in Plasmodium falciparum malaria.

Authors:  Paul D Roepe
Journal:  Future Microbiol       Date:  2009-05       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.